CIRM Clinical Trials

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization. Visit our Funding Opportunities page to apply for clinical trial research funding.

0

CIRM-Funded Clinical Trials

Disease AreasInvestigatorOrganizationPhaseTrial StatusTarget EnrollmentDetail
Age-related macular degeneration Dr. Mark S Humayun University of Southern California Phase 1 Closed 16
Corneal Damage Dr. Sophie X Deng University of California, Los Angeles Phase 1 Recruiting 20
Retinitis Pigmentosa Clive Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
Bone or Cartilage Disease
Hearing Loss
Intellectual Disability
Metabolic Disorders
Vision Loss		 Dr Robert Hayes Immusoft Corporation Phase 1 Launching N/A
Retinitis Pigmentosa Paul Bresge Ray Therapeutics, INC Phase 1 Launching N/A
Retinitis Pigmentosa Dr. Henry John Klassen University of California, Irvine Phase 1/2 Completed 28
Age-related macular degeneration Dr. Jeffrey H Stern Luxa Biotechnology Phase 1/2 Launching N/A
Retinitis Pigmentosa Henry John Klassen jCyte, Inc Phase 2 Completed 84
Corneal Damage R. Kim Brazzell Combangio, Inc. Phase 2 Launching N/A
Age-related macular degeneration Dr Jane S Lebkowski Regenerative Patch Technologies LLC Phase 2 Launching N/A
Retinitis Pigmentosa Henry John Klassen jCyte, Inc Phase 2 Completed 84